Monogenic diabetes and the role of the diabetes nurse

REFERENCES

• Hammersley S, et al Prevalence of non-type 1 diabetes in paediatric diabetes. Diabet Med 2013;30 (Suppl 1) :24 (A67).
   Google Scholar
• Hudson MM, et al. A population-based approach to genetic testing defines the preva-lence of maturity onset diabetes of the young (MODY) in patients with diabetes diagnosed under 30 years as 3%. Diabet Med 2013; 30(Suppl 1) :24 (A68).
   Google Scholar
• Shepherd M, et al A genetic diagnosis of HNFlA diabetes alters treatment and improves glycaemic control in the majority of insulin treated patients. Diabet Med 2009;26:437–41.
   PubMed Web of Science ®Google Scholar
• Pearson ER, et al. Sensitivity to sulphony-lureas in patients with HNFlA mutations: evi-dence for pharmacogenetics in diabetes. Diabet Med 2000;17:543–5.
   PubMed Web of Science ®Google Scholar
• Shepherd M, et al No deterioration in gly-caemic control in HNF-1 alpha MODYfollow-ing transfer from long-term insulin to sulpho-nylureas. Diabetes Care 2003;26:3191–2.
   PubMed Web of Science ®Google Scholar
• Shepherd M. 'I'm amazed I've been able to come off injections': Patients' perceptions of genetic testing in diabetes. Report of the 2003 Janet Kinson Lecture. Prad Diabetes Int 2003;20:338–43.
   Google Scholar
• Pearson ER, et al. Genetic cause of hypergly-caemia and response to treatment in dia-betes. Lancet 2003;362:1275–81.
   PubMed Web of Science ®Google Scholar
• Stride A, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase muta-tions does not alter glycaemia. Diabetologia 2014; 57: 54–6. [ Epub 2013 Oct 4.]
   Web of Science ®Google Scholar
• Murphy R, et al Clinical implications of a molecular genetic classification of mono-genic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200–13.
   PubMedGoogle Scholar
• Shields BM, et al. Maturity-onset diabetes of the young (MODY) in the UK; how many cases are we missing? Diabetologia 2010; 53:2504–8.
   PubMed Web of Science ®Google Scholar
• Stride A, Hattersley AT. Different genes dif-ferent diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002; 34:207–16.
   PubMed Web of Science ®Google Scholar
• Edghill EL, et al Permanent neonatal dia-betes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord 2010; 11:193–8.
   Web of Science ®Google Scholar
• Flanagan SE, et al. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by geno-type. Diabetologia 2006;49:1190–7.
   PubMed Web of Science ®Google Scholar
• Gloyn AL, et al Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838–49. Erratum in: N Engif Med 2004; 351: 1470.
   Google Scholar
• McDonald TJ, et al Stability and repro-ducibility of a single sample urinary Gpep-tide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009; 55:2035–9.
   PubMed Web of Science ®Google Scholar
• Besser REJ, et al. Urinary C-peptide creatinine ratio (UCPCR) is a practical outpatient tool for identifying HNF1A/HNF4A MODY from long duration type 1 diabetes. Diabetes Care 2011;34:286–91.
   Web of Science ®Google Scholar
• Bowman P, et al. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with type 2 diabetes. Diabet Med 2012;29:90–3.
   PubMed Web of Science ®Google Scholar
• Besser RE, et al. Urine Gpeptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011;34:607–9.
   PubMed Web of Science ®Google Scholar
• McDonald TJ, et al. Islet autoantibodies can discriminate maturity onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28:1028–33.
   Web of Science ®Google Scholar
• Sabbah E, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326–32.
   PubMed Web of Science ®Google Scholar
• Shields BM, et al. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012;55:1265–72.
   Web of Science ®Google Scholar
• Shepherd M, et al. Differential diagnosis: Identifying people with monogenic diabetes. J Diabetes Nurs 2010;14:342–7.
   Google Scholar
• Stride A, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-lalpha mutation carriers. Diabetes Care 2005;28:1751–6.
   Web of Science ®Google Scholar
• Steele AM, et al. Increased all-cause and cardiovascular mortality in monogenic dia-betes as a result of mutations in the HNFlA gene. Diabet Med 2010;27:157–61.
   Web of Science ®Google Scholar
• Pearson ER, et al. Macrosomia and hyperin-sulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007;4(4) :e118.
   PubMed Web of Science ®Google Scholar
• Pearson ER, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4 mutations in a large European collection. Diabetologia 2005;48:878–85.
   PubMed Web of Science ®Google Scholar
• Steele AM, et al. Low prevalence of diabetes complications after 48 years of mild hyper-glycaemia in patients with glucokinase muta-tions supports current glycaemic targets for diabetes management. Diabet Med 2013; 30(Suppl 1):A70.
   Google Scholar
• Steele AM, et al. Use of HbAk in the identifi-cation of patients with hyperglycaemia caused by a glucokinase mutation: observa-tional case control studies. PLoS One 2012; 8(6) :e65326.
   Google Scholar
• Ellard S, et al. A high prevalence of glucoki-nase mutations in gestational diabetic sub-jects selected by clinical criteria. Diabetologia 2000;43:250–3.
   PubMed Web of Science ®Google Scholar
• Shepherd M, et al. Dimensions of personal loss and gain associated with a rare genetic type of diabetes. Illness, Crisis and Loss 2003;11:362–76.
   Google Scholar
• Bingham C, et al. Abnormal nephron devel-opment associated with a frameshift muta-tion in the transcription factor hepatocyte nuclear factor-113. Kidney Int 2000;57: 898–907.
   PubMed Web of Science ®Google Scholar
• Bingham C, Hattersley AT. Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-113. Nephrol Dial Transplant 2004;19:2703–8.
   PubMed Web of Science ®Google Scholar
• Bellanné-Chantelot C, et al. Clinical spectrum associated with hepatocyte nuclear factor-lbeta mutations. Ann Intern Med 2004; 140:510–7.
   PubMed Web of Science ®Google Scholar
• Shepherd M. Transforming lives: transferring patients with neonatal diabetes from insulin to sulphonylureas. Eur Diabetes Nurs 2006; 3:137–42.
   Google Scholar
• Hattersley AT, Ashcroft FM. Activating muta-tions in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503–13.
   PubMed Web of Science ®Google Scholar
• Proks P, et al. A heterozygous activating muta-tion in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006;15:1793–800.
   PubMed Web of Science ®Google Scholar
• Gloyn AL, et al. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Genet 2006;14:824–30.
   PubMed Web of Science ®Google Scholar
• Pearson ER, et al.; Neonatal Diabetes International Collaborative Group. Switch-ing from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 muta-tions. N Engl J Med 2006;355:467–77.
   PubMed Web of Science ®Google Scholar
• Sagen JV, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713–8.
   PubMed Web of Science ®Google Scholar
• Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005;37:186–95.
   PubMed Web of Science ®Google Scholar
• Slingerland AS, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008; 25:277–81.
   Web of Science ®Google Scholar
• Slingerland AS, et al. Improved motor devel-opment and good long-term glycaemic con-trol with sulfonylurea treatment in a patient with the syndrome of intermediate develop-mental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006;49:2559–63.
   PubMed Web of Science ®Google Scholar
• Edghill EL, et al. Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J Clin Enclocrinol Metab 2007;92:1773–7.
   Web of Science ®Google Scholar